SCHEMBL29608973

SCHEMBL29608973

Cc1ccc(S(=O)(=O)n2cc(-c3ccc(C(=O)N(C)C)cc3)c3nc(Br)cnc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.38
CYP1A2 P05177 8/20 0.38
CYP3A4 P08684 8/20 0.38
HSD17B10 Q99714 5/20 0.38
ALDH1A1 P00352 4/20 0.38
ALOX15 P16050 3/20 0.38
CYP2C19 P33261 3/20 0.38
ATR Q13535 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
JAK2 O60674 1/20 0.37
TSHR P16473 4/20 0.36
CYP2D6 P10635 3/20 0.36
CLK4 Q9HAZ1 3/20 0.36
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28513374 0.89 PTPN11 (0.42) PTPN11L3MBTL1ALDH1A1ATRMEN1
SCHEMBL29607743 0.89 PTPN11 (0.45) PTPN11L3MBTL1CYP3A4ALDH1A1ATR
SCHEMBL28711868 0.88 PTPN11 (0.41) PTPN11L3MBTL1CYP3A4ALDH1A1MEN1
SCHEMBL28701348 0.88 PTPN11 (0.41) PTPN11L3MBTL1CYP3A4ALDH1A1MEN1
SCHEMBL28504212 0.88 PTPN11 (0.41) PTPN11L3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL28701346 0.88 PTPN11 (0.41) PTPN11L3MBTL1CYP3A4ALDH1A1MEN1
SCHEMBL29608813 0.87 PTPN11 (0.42) PTPN11L3MBTL1CYP1A2CYP3A4HSD17B10
SCHEMBL28720149 0.86 ALDH1A1 (0.49) PTPN11L3MBTL1CYP1A2CYP3A4HSD17B10
SCHEMBL28706978 0.86 PTPN11 (0.40) PTPN11L3MBTL1ALDH1A1ATRSMN1; SMN2
SCHEMBL30215940 0.85 PTPN11 (0.54) PTPN11L3MBTL1CYP1A2CYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459958-B2 Tricyclic compounds as HPK1 inhibitor and the use thereof BEONE MEDICINES I GMBH (CH) 2025-11-04 US disclosed
US-12454534-B2 Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof BEONE MEDICINES I GMBH (CH) 2025-10-28 US disclosed
CN-115073474-B Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof 百济神州有限公司 2024-10-18 CN disclosed
CN-114127067-B Tricyclic compounds as HPK1 inhibitors and uses thereof 百济神州有限公司 2024-08-23 CN disclosed
EP-4377318-A1 PYRROLO [2, 3-B] PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND THE USE THEREOF BeiGene, Ltd. (KY) 2024-06-05 EP disclosed
CN-118043324-A Pyrrolo [2,3-b ] pyrazine-based bifunctional compounds as HPK1 degradants and uses thereof 百济神州有限公司 2024-05-14 CN disclosed
CN-112239473-B Process for preparing tricyclic compounds as HPK1 inhibitors 百济神州(北京)生物科技有限公司 2023-12-08 CN disclosed
WO-2023006063-A1 PYRROLO [2, 3-b] PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND THE USE THEREOF BEIGENE, LTD. (KY) 2023-02-02 WO disclosed
CN-115028639-A Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof 百济神州有限公司 2022-09-09 CN disclosed
US-20220267354-A1 TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2022-08-25 US disclosed
US-20220267333-A1 PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2022-08-25 US disclosed
EP-3994136-A1 PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF BeiGene, Ltd. (KY) 2022-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267354-A1 TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF ULK1, SBK1, PHKG1 PTPN11 1341/4885L3MBTL1 3378/4885CYP1A2 3077/4885
US-20220267333-A1 PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF PDXK, STK25, STK35 PTPN11 593/4885L3MBTL1 4270/4885CYP1A2 2216/4885
US-12454534-B2 Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof PDXK, STK25, STK35 PTPN11 593/4885L3MBTL1 4270/4885CYP1A2 2216/4885
US-12459958-B2 Tricyclic compounds as HPK1 inhibitor and the use thereof ULK1, SBK1, PHKG1 PTPN11 1341/4885L3MBTL1 3378/4885CYP1A2 3077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.